Hypogammaglobulinemia in patients with multiple sclerosis receiving disease modifying therapies: disproportionality analysis using the EudraVigilance database
The study highlights the importance of monitoring for the occurrence of hypogammaglobulinemia and infections in patients receiving ocrelizumab, ofatumumab and rituximab for MS. These ADRs can be extremely serious and highlight the need for ongoing research to optimize their safety profiles.
Authors
- Marina Di Domenico (ORCID: https://orcid.org/0000-0002-6201-4200)
- Concetta Rafaniello (ORCID: https://orcid.org/0000-0002-7107-4280)
- Daniele Di Giulio Cesare
- Ugo Trama (ORCID: https://orcid.org/0000-0001-9473-8943)
- Nunzia Balzano
- Cristina Scavone (ORCID: https://orcid.org/0000-0002-9216-922X)
- Raffaella Di Napoli (ORCID: https://orcid.org/0009-0009-4497-3836)
- Paola Della Monica
- Giorgia Teresa Maniscalco (ORCID: https://orcid.org/0000-0002-0679-9939)
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- Regione Campania (IT)
- Pharmac (NZ)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-16
- DOI
- https://doi.org/10.1080/14740338.2025.2493795
- Citations
- 1
- Primary Topic
- Immunodeficiency and Autoimmune Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.80